Prime Medicine Inc (PRME)

Currency in USD
3.790
+0.090(+2.43%)
Closed·
3.7900.000(0.00%)
·

Prime Medicine Inc Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address
60 First Street, Cambridge, 02141, United States
Phone
617 465 0013

Top Executives

Name
Title
Since
Age
Jeffrey D. MarrazzoExecutive Chair202547
Allan ReineCEO & Director202551
David R. LiuCo-Founder & Member of Scientific Advisory Board2022-
David P. SchenkeinIndependent Director201969
Michael A. KellyIndependent Director202169
Kaye I. Foster-CheekIndependent Director202166
Robert Taylor NelsenIndependent Director202064
Wendy K. ChungIndependent Director202156
Thomas J. CahillIndependent Director202139
Yvonne Yu-Hsuan ChenMember of Scientific Advisory Board2022-
Agnieszka CzechowiczMember of Scientific Advisory Board2022-
Guangping GaoMember of Scientific Advisory Board2022-
James HaberMember of Scientific Advisory Board2022-
Anastasia KhvorovaMember of Scientific Advisory Board202257
Ben KleinstiverMember of Scientific Advisory Board2022-
Muthiah ManoharanMember of Scientific Advisory Board202273
Jay ShendureMember of Scientific Advisory Board2022-
Samuel H. SternbergMember of Scientific Advisory Board2022-
Shengdar Q. TsaiMember of Scientific Advisory Board2022-
Eric N. OlsonMember of Scientific Advisory Board--
Gerald SchwankMember of Scientific Advisory Board2023-
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.